AAV-8 Vector Capsid Mutation for Targeted Liver Cancer Gene Silencing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for liver cancer, particularly hepatocellular carcinoma (HCC), face challenges in efficiently and safely delivering miRNA-based therapies due to non-specific targeting and the inadequacy of existing delivery methods, which often result in palliative treatments with poor prognosis.

Innovation Solution

A recombinant adeno-associated virus (rAAV) vector, specifically AAV-8-pre-miRNA-101, is used to enforce the expression of pre-miR-101, targeting and silencing the metastasis-promoting gene EzH2, utilizing a self-complementary vector with mutated capsids for enhanced transduction efficiency and minimal toxicity, administered via hepatic portal vein or intravenous injection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If miRNA-based therapy is used to target cancer genes, then therapeutic efficacy is improved, but delivery safety and specificity deteriorate due to non-specific targeting

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidnon-specific targeting

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses adeno-associated virus (AAV) as an intermediary delivery vehicle to transport pre-miR-101 specifically to liver cancer cells. The AAV vector system includes a capsid protein for targeted delivery, an ITR sequence for viral genome replication, and a promoter sequence for controlled gene expression, thereby achieving specific delivery while avoiding non-specific targeting effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs tissue-specific promoters and capsid modifications to enable the AAV vector to selectively target and deliver miR-101 only to hepatocellular carcinoma cells in the liver, rather than systemically distributing the therapeutic agent throughout the body, thus improving local efficacy while reducing off-target effects

Inventive Principle:

Principle #3Local quality

2Ease of operation

If conventional delivery methods are used for miRNA therapy, then ease of administration is improved, but transduction efficiency deteriorates

Engineering Contradiction:

Improveease of administrationVSAvoidtransduction efficiency

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent utilizes self-complementary AAV vectors that can directly transduce non-dividing hepatocytes without requiring cell division, and employs hepatic-specific promoters to control gene expression, thereby achieving efficient transduction of target cells while maintaining ease of intravenous or portal vein administration

Inventive Principle:

Principle #35Parameter changes

3Reliability

If viral vectors are used to enhance transduction efficiency, then transduction efficiency is improved, but toxicity increases

Engineering Contradiction:

Improvetransduction efficiencyVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent employs replication-deficient recombinant AAV vectors that cannot produce infectious progeny and are cleared from the body after delivering their therapeutic payload, thereby achieving sustained gene expression without the long-term persistence and potential toxicity associated with replication-competent viral vectors

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The AAV vector acts as a temporary intermediary that delivers the pre-miR-101 gene to hepatocytes and then is degraded, leaving only the therapeutic miRNA expression behind, thus achieving efficient transduction while minimizing long-term viral presence and associated toxicity

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The AAV-8-pre-miRNA-101 vector effectively inhibits EzH2 expression, leading to reduced tumor growth and metastasis in liver cancer cells, offering a promising therapeutic option with targeted and sustained gene silencing, potentially improving treatment outcomes for HCC.

Implementation Method 1

miRNAs have been recognized as one of the major regulatory gene families that utilize identical cellular enzymes/pathways as siRNA with similar mechanisms leading to translational repression of target mRNA

Methodology Applied

Scientific EffectRNA interference (RNAi):

Implementation Method 2

enforced expression of pre-miR-101, targeting and silencing the metastasis-promoting gene EzH2

Methodology Applied

Scientific EffectGene silencing:

Implementation Method 3

A recombinant adeno-associated virus (rAAV) vector, specifically AAV-8-pre-miRNA-101, is used to enforce the expression of pre-miR-101

Methodology Applied

Scientific EffectViral transduction:

Implementation Method 4

utilizing a self-complementary vector with mutated capsids for enhanced transduction efficiency and minimal toxicity

Methodology Applied

Scientific EffectCapsid mutation for enhanced transduction:

Data Source

PatentUS9163261B2Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer

Publication Date: 2015.10.20 KOLLIPARA KOTESWARA RAO

AI summary

Adeno-associated virus 2/8-microRNA-101(AAV2/8-miR-101) therapy for liver cancer is provided. In particular, the invention provides a recombinant AAV 2/8 vector, comprising mutated capsid, for the enforced expression of pre-miR-101 and for the treatment of liver cancer.